Blood: Effective disease risk index for allogeneic hematocyte transplantation in children with blood tumors

The Disease Risk Index (DRI) was developed for adult patients with blood malignancies transplanted from hematopoietic stem cells and is also used to stratte children and adolescents based on disease risk.
In this study, researchers analyzed 2,569 patients under the age of 18 who received hematocyte transplants for acute myeloid leukemia (AML; n=1224) or acute lymphoblastic leukemia (ALL; n=1345) to develop and validate DRIs that could be stratified according to the disease risk of AML/ALL children/adolescents.
development and validation queues for each disease are randomly generated, distributed at 1:1, and separate prognosto models are built for each disease.
the survival and total survival of leukemia was divided into four risk groups for AML patients, depending on age, cytogenetic risk, and disease status, including the lowest residual disease status at the time of transplantation.
5-year leukemia-free survival rates were 78%, 53%, 40% and 25% in patients in the low-risk group (0), medium-risk group (2, 3, 5 points), high-risk group (7, 8 points) and very high-risk group (8 points), respectively.
for ALL patients, the group was divided into three risk groups based on age and disease status, including the lowest residual disease condition at the time of transplantation.
5-year leukemia-free survival rates were 68%, 51% and 33% for patients in the low-risk group (0 points), medium-risk group (2 to 4 points) and high-risk group (≥5), respectively.
the study confirmed that risk group strat three-tiering could be used for total survival rates, with AML and ALL children/adolescents floating between 80% and 33% and 73% to 42%, respectively.
in summary, this validated Child/Adolescent Disease Risk Index (DRI) incorporates age and residual disease status parameters and can be used to improve stratified and prognostic projections of allogeneic hematopoietic stem cell transplantation in such patients.
。